Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KYMR 
Kymera Therapeutics Inc (KYMR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: KYMR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $60.37
1 Year Target Price $60.37
| 14 | Strong Buy |
| 3 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 72.93% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.97B USD | Price to earnings Ratio - | 1Y Target Price 60.37 |
Price to earnings Ratio - | 1Y Target Price 60.37 | ||
Volume (30-day avg) 20 | Beta 2.18 | 52 Weeks Range 19.45 - 53.27 | Updated Date 08/15/2025 |
52 Weeks Range 19.45 - 53.27 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.49 |
Earnings Date
Report Date 2025-08-01 | When - | Estimate -0.8325 | Actual -0.95 |
Profitability
Profit Margin - | Operating Margin (TTM) -736.82% |
Management Effectiveness
Return on Assets (TTM) -19.92% | Return on Equity (TTM) -33.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2390994155 | Price to Sales(TTM) 66.44 |
Enterprise Value 2390994155 | Price to Sales(TTM) 66.44 | ||
Enterprise Value to Revenue 53.48 | Enterprise Value to EBITDA -9.49 | Shares Outstanding 71497600 | Shares Floating 47079738 |
Shares Outstanding 71497600 | Shares Floating 47079738 | ||
Percent Insiders 2.45 | Percent Institutions 107.06 |
Upturn AI SWOT
Kymera Therapeutics Inc
Company Overview
History and Background
Kymera Therapeutics Inc. was founded in 2016. It is a clinical-stage biopharmaceutical company focused on discovering and developing novel protein degradation therapies. The company utilizes its proprietary targeted protein degradation platform, Pegasusu2122, to design small molecule therapeutics that selectively degrade disease-causing proteins.
Core Business Areas
- Targeted Protein Degradation: Kymera's core business revolves around developing therapies using targeted protein degradation. This approach aims to selectively eliminate disease-causing proteins, offering a potential advantage over traditional therapies that only inhibit protein function.
- Drug Discovery and Development: The company focuses on discovering and developing small molecule drugs for various diseases, including immune-inflammatory diseases and oncology.
- Platform Technology: Kymera's Pegasusu2122 platform is central to its drug development efforts, enabling the identification and design of protein degraders.
Leadership and Structure
Nello Mainolfi is the President and CEO of Kymera Therapeutics. The organizational structure involves research, development, clinical, and commercial teams focused on advancing the company's pipeline.
Top Products and Market Share
Key Offerings
- KT-474 (IRAK4 degrader): KT-474 is Kymera's lead clinical program, targeting IRAK4 for the treatment of immune-inflammatory diseases. Currently in Phase 2 clinical trials. Competitors developing IRAK4 inhibitors include companies like Kineta, but KT-474's degradation mechanism offers a potentially differentiated approach. Market share data is not yet available as it's in clinical development.
- KT-333 (STAT3 degrader): KT-333 is a STAT3 degrader being developed for oncology indications. Currently in Phase 1 clinical trials. Competitors targeting STAT3 include companies developing antisense oligonucleotides and inhibitors. Market share data is not yet available as it's in clinical development.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and rapidly evolving, with a focus on developing innovative therapies for unmet medical needs. Targeted protein degradation is an emerging field with the potential to address diseases that are difficult to treat with traditional approaches.
Positioning
Kymera is a leader in the targeted protein degradation field, leveraging its proprietary Pegasusu2122 platform to develop novel therapies. Its competitive advantage lies in its expertise in protein degradation and its focus on developing differentiated drugs.
Total Addressable Market (TAM)
The TAM for targeted protein degradation therapies is potentially very large, covering a broad range of diseases. Kymera is positioned to capture a significant portion of this market with its innovative platform and pipeline.
Upturn SWOT Analysis
Strengths
- Proprietary Pegasusu2122 platform
- Strong scientific team
- First-mover advantage in targeted protein degradation
- Robust pipeline of drug candidates
- Strategic partnerships with established pharmaceutical companies
Weaknesses
- Early-stage clinical development
- High R&D costs
- Reliance on a single technology platform
- Potential for clinical trial failures
- Competition from established pharmaceutical companies
Opportunities
- Expansion into new therapeutic areas
- Strategic collaborations and partnerships
- Advancements in protein degradation technology
- Positive clinical trial results
- Potential for breakthrough therapies
Threats
- Competition from other targeted protein degradation companies
- Clinical trial failures
- Regulatory hurdles
- Patent disputes
- Changes in healthcare policy
Competitors and Market Share
Key Competitors
- VRTX
- LLY
- BIIB
- GILD
Competitive Landscape
Kymera's advantages include its focus on targeted protein degradation and its proprietary platform. Its disadvantages include its early stage of development and competition from established pharmaceutical companies. These companies have other drugs and platforms, and Kymera is focused on protein degradation.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by preclinical and early clinical development milestones.
Future Projections: Future growth is projected to be driven by successful clinical trial outcomes, regulatory approvals, and commercialization of products.
Recent Initiatives: Recent initiatives include advancing KT-474 and KT-333 through clinical trials, expanding the pipeline with new programs, and strengthening partnerships.
Summary
Kymera Therapeutics is an innovative biopharmaceutical company pioneering targeted protein degradation. Its Pegasus platform and clinical pipeline, particularly KT-474, hold significant promise. However, it faces challenges inherent in drug development, including clinical trial risks and competition. Successful clinical trials and strategic partnerships are essential for future growth, while managing cash burn remains a key consideration.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Kymera Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kymera Therapeutics Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2020-08-21 | Co-Founder, President, CEO & Director Dr. Nello Mainolfi M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 218 | Website https://www.kymeratx.com |
Full time employees 218 | Website https://www.kymeratx.com | ||
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.